mRNA-1273-P901, Real-World Study of the Effectiveness of Moderna COVID-19 Vaccine

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/106671
• EU PAS number:
  EUPAS106670
• Study ID:
  106671
• Official title and acronym:
  mRNA-1273-P901, Real-World Study of the Effectiveness of Moderna COVID-19 Vaccine
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC).
• Study status:
  Ongoing

Research institutions and networks

Institutions

Kaiser Permanente Southern California (KPSC)

Study timelines

Date when funding contract was signed

Actual: 26/01/2021

Study start date

Actual: 18/12/2020

Data analysis start date

Planned: 31/01/2024

Date of final study report

Planned: 14/04/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

ModernaTX

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)

Other study registration identification numbers and links

NCT05933304, https://clinicaltrials.gov/study/NCT05933304?term=NCT05933304&rank=1